University of California

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Retrieved on: 
måndag, juni 3, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ASCO, University of California, Mutation, Patient, Annual general meeting, Phases of clinical research, NSCLC, Society, Puma Biotechnology, Metastasis, Aurora kinase A, Alisertib, EGFR, Clinical trial, OS, PFS, MTD, University, Lung cancer, Abstract, TP53, BID, Poster, CDT, Pharmaceutical industry

A copy of the poster is available on the Puma website.

Key Points: 
  • A copy of the poster is available on the Puma website.
  • This open-label, single-center Phase I/Ib study enrolled 21 evaluable patients with stage IV EGFR-mutated NSCLC (EGFR driver mutation: 76.1% exon 19 deletion; 14.3% L858R; 9.5 % L861Q) who had progressed on osimertinib monotherapy.
  • 47.6% of patients had previously received only first-line osimertinib monotherapy, while 52.3% had received two or greater prior lines of therapy.
  • Intermittent alisertib 30 mg BID was identified as the MTD and RP2D in combination with osimertinib 80 mg daily.

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

Retrieved on: 
onsdag, maj 29, 2024
ENDO, Private practice, SLRN, Jules Stein Eye Institute, Orbital, Immunoglobulin G, University, FDA, TED, Oculoplastics, Endocrine system, University of California, Graves' ophthalmopathy

LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED) will be shared as a late breaking oral presentation at the Endocrine Society’s Annual Meeting (ENDO 2024), taking place from June 1-4 in Boston, MA. Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R is the only FDA-approved mechanism of action for the treatment of TED.

Key Points: 
  • LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED) will be shared as a late breaking oral presentation at the Endocrine Society’s Annual Meeting (ENDO 2024), taking place from June 1-4 in Boston, MA.
  • Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R).
  • Inhibition of IGF-1R is the only FDA-approved mechanism of action for the treatment of TED.
  • Presentation details are as follows:
    Presenter: Dr. Shoaib Ugradar, Department of Orbital and Oculoplastic Surgery, Private Practice; The Jules Stein Eye Institute, University of California

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Retrieved on: 
torsdag, maj 23, 2024
Risk, Obesity, ESS, ResMed, Ageing, SAN, ATS, Woman, ASV, Therapy, University of California, ASX, Plan, Health care, LVEF, Coronary artery disease, Sleep, Grenoble Alpes University, Literature review, Natural language processing, Conference, CSA, Circulatory system, Meta-analysis, BMI, AHI, Clinical trial, NIV, Obstructive sleep apnea, Qualitative Research (journal), Comorbidity, Depression, NYHA, Sleep disorder, Hospital, Research, OSA, COPD, Central sleep apnea, PAP, Patient, Education, Qualitative, RMD, Prevalence, University, Overalls, Mortality, Death, Abstract, Economy, Adaptation, Quality of life, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD) in collaboration with leading scientists including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.

Key Points: 
  • The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
  • Several studies demonstrated findings showing continued effectiveness of PAP therapies for patients with sleep disorder conditions like obstructive sleep apnea.
  • This finding demonstrates a correlation between the use of PAP therapy and a reduction in use of healthcare resources.
  • Two studies evaluated the effects of Adaptive Servo-Ventilation (ASV) therapy in two populations, patients with TE-CSA and patients on long-term opioid therapy.

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Retrieved on: 
tisdag, maj 21, 2024
Proton, Principal, Bangladesh Technical Education Board, Patient, Pharmacokinetics, MASH, Liver, Liver disease, University, Doctor of Philosophy, Therapy, Armed Forces Medical College, SAN, MBA, UCSD, MD, NIDDK, Magnetic resonance, NAFLD, Magnetic resonance imaging, Division, Digestive, Safety, Kidney, University of California, Hepatology, NIH

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024. The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.

Key Points: 
  • The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.
  • “Completing enrollment in our first Phase 2a trial is a tremendous accomplishment for the Aligos team,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • In addition, I’d like to welcome Dr. Rohit Loomba as our Principal Investigator for the HERALD study.
  • “The excellent potency and PK profile makes ALG-055009 a compelling potential treatment option for MASH patients.

Infrared Sauna Use in UCSF Clinical Trial Shows Promise in Combating Depression

Retrieved on: 
måndag, maj 20, 2024
Hearing, Doctor of Philosophy, UCSF, Area studies, CBT, MDD, Clinical trial, University, Depression, Cognitive behavioral therapy, Mental Health Awareness Month, WBH, Alternative medicine, Canadian International Council, DSM-IV codes, Psychotherapy, Lifting, Mason, University of California, Pharmaceutical industry

The study used the The Curve™ Far Infrared Sauna Dome , manufactured by Clearlight ®, the industry leader in infrared sauna and pioneer in innovative health and wellness solutions.

Key Points: 
  • The study used the The Curve™ Far Infrared Sauna Dome , manufactured by Clearlight ®, the industry leader in infrared sauna and pioneer in innovative health and wellness solutions.
  • Dr. Mason began the clinical trial after being inspired by prior work showing that infrared heat treatment caused rapid reductions in depression.
  • Preliminary results from prior studies and Dr. Mason’s most recent study suggests that infrared heat treatment may help significantly reduce depression symptoms.
  • While Dr. Mason’s future clinical trial testing efficacy will take several years, early results from her feasibility studies are showing that whole-body hyperthermia may reduce depression symptoms.

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

Retrieved on: 
torsdag, maj 23, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Dana–Farber Cancer Institute, Neck, Risk, Liver, Avelumab, DDR, Carcinoma, University of California, Health care, Abstract (summary), Survival, Cough, BSC, CEACAM5, Head, Atri, ADC, Abstract, Phase II, ATM, Quality of life (healthcare), CRT, Phase, Neoplasm, Safety, Institute of Cancer Research, Cancer, ASCO, Society, IAP, BIRC, Antigen, Patient, Pharmacokinetics, ADP, DNA, PARP, Phases of clinical research, University, Death, Clinical trial, Brain, Chemoradiotherapy, Annual general meeting, Pharmaceutical industry

Merck, a leading science and technology company, today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, Chicago.

Key Points: 
  • Merck, a leading science and technology company, today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, Chicago.
  • Data from 40 patients treated across seven dose levels in Part 1A of the study showed encouraging clinical activity and a manageable and predictable safety profile in this population.
  • New findings for tuvusertib, the lead oral ATRi asset from the company’s portfolio of DNA damage response (DDR) inhibitors (Abstracts 3018, 2612, 2614).
  • Data show a manageable safety profile and preliminary efficacy in patients with advanced solid tumors, confirming suitability of this combination for further evaluation.

EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

Retrieved on: 
torsdag, maj 23, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Dana–Farber Cancer Institute, Neck, Risk, Liver, Avelumab, DDR, Carcinoma, University of California, Health care, Abstract (summary), Survival, Cough, BSC, Merck Serono, CEACAM5, Head, Atri, ADC, Abstract, Phase II, Merck, ATM, Quality of life (healthcare), CRT, Phase, Neoplasm, Safety, Institute of Cancer Research, Cancer, ASCO, Society, IAP, BIRC, Antigen, Patient, Pharmacokinetics, ADP, DNA, PARP, Phases of clinical research, University, Merck Group, Death, Clinical trial, Brain, Chemoradiotherapy, Annual general meeting, Pharmaceutical industry

Data from 40 patients treated across seven dose levels in Part 1A of the study showed encouraging clinical activity and a manageable and predictable safety profile in this population.

Key Points: 
  • Data from 40 patients treated across seven dose levels in Part 1A of the study showed encouraging clinical activity and a manageable and predictable safety profile in this population.
  • New findings for tuvusertib, the lead oral ATRi asset from the company’s portfolio of DNA damage response (DDR) inhibitors (Abstracts 3018, 2612, 2614).
  • Data from the DDRiver™ Clinical Trials program highlight the potential of the investigational oral ataxia telangiectasia and RAD3-related inhibitor (ATRi) tuvusertib in various combinations across solid tumors.
  • Data show a manageable safety profile and preliminary efficacy in patients with advanced solid tumors, confirming suitability of this combination for further evaluation.

The National Cyber League Announces Official Spring 2024 Cyber Power Rankings for High Schools and Colleges

Retrieved on: 
torsdag, maj 9, 2024
University, CrowdStrike, California State University, Chico, School, NCL, Innovation, University of California, Student, SANS Institute, Colorado State University Pueblo, Face, Workforce, Arms industry

CHEVY CHASE, Md., May 9, 2024 /PRNewswire-PRWeb/ -- The National Cyber League concluded the Spring 2024 NCL Competition with participation from 8,017 students and 737 high schools, colleges, and universities from all over the United States, representing all 50 states.

Key Points: 
  • The National Cyber League concluded the Spring 2024 NCL Competition with participation from all over the United States, representing all 50 states.
  • Each season the NCL publishes its Cyber Power Rankings of the top 100 schools within the competition.
  • CHEVY CHASE, Md., May 9, 2024 /PRNewswire-PRWeb/ -- The National Cyber League concluded the Spring 2024 NCL Competition with participation from 8,017 students and 737 high schools, colleges, and universities from all over the United States, representing all 50 states.
  • The Cyber Power Rankings is a published list of the top 100 schools within the NCL, representing the hard work and skills of collegiate and high school students.

Editas Medicine Announces First Quarter 2024 Results and Business Updates

Retrieved on: 
onsdag, maj 8, 2024
Rubius, CRISPR, Research, Paratriathlon, University of California, Intellectual property, CAFC, SCD, BMY, Editas Medicine, Gene editing, Adolescence, Medicine, Leber congenital amaurosis, Bristol Myers Squibb, Therapy, Vertex Pharmaceuticals, Cas9, Guide, Change, LSID, Emmanuelle, Blas, Public expenditure, Human, University of Vienna, Collaboration, CVC, Bluebird bio, TDT, Sale, Cancer, Cell, Quality, Senior, Patent, Patient, Liver, Gene, Society, Pharmaceutical industry

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.
  • “We made significant progress in all three pillars of our strategy this quarter, including reni-cel, in vivo, and business development, including intellectual property,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.
  • ET to provide and discuss a corporate update and financial results for the first quarter of 2024.
  • To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

Retrieved on: 
torsdag, maj 9, 2024
Neurology, Mental Health, Health, Pharmaceutical, Clinical Trials, Schizophrenia, CMO, Neuroscience, University of Toronto, University of California, Cognition, Vortioxetine, Biological Psychiatry (journal), Biomarker, Prevalence, Into, Diagnosis, Deficit spending, Drug development, Area studies, Remind, Depression, Data, Pharmacodynamics, EEG, Bipolar, Trial, Chair, Volunteering, Lab, Cognitive deficit, Doctor of Philosophy, Society, University, Cyclothymia, Randomness, ASCP, Pharmaceutical industry

“Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.

Key Points: 
  • “Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.
  • Importantly, we have systematically identified and prospectively replicated neurobiological markers linked to cognitive impairment associated with schizophrenia in a comprehensive analysis inclusive of all major candidate biomarkers.
  • New analysis of vortioxetine Phase 3 data demonstrates that baseline cognitive performance is not a moderator of response to vortioxetine.
  • A notable relationship between theta response and processing speed, which is thought to underpin cognitive impairment in schizophrenia, was observed.